HRP20192055T1 - Poli-(laktid/glikolid) sa smanjenim efektom naglog oslobađanja i metode za proizvodnju polimera - Google Patents
Poli-(laktid/glikolid) sa smanjenim efektom naglog oslobađanja i metode za proizvodnju polimera Download PDFInfo
- Publication number
- HRP20192055T1 HRP20192055T1 HRP20192055TT HRP20192055T HRP20192055T1 HR P20192055 T1 HRP20192055 T1 HR P20192055T1 HR P20192055T T HRP20192055T T HR P20192055TT HR P20192055 T HRP20192055 T HR P20192055T HR P20192055 T1 HRP20192055 T1 HR P20192055T1
- Authority
- HR
- Croatia
- Prior art keywords
- copolymer material
- reduced
- release
- plg
- plg copolymer
- Prior art date
Links
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 title claims 5
- 229920000642 polymer Polymers 0.000 title 1
- 229920001577 copolymer Polymers 0.000 claims 31
- 239000000463 material Substances 0.000 claims 22
- 230000000694 effects Effects 0.000 claims 8
- 239000002904 solvent Substances 0.000 claims 6
- 238000013270 controlled release Methods 0.000 claims 5
- 238000009472 formulation Methods 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical group CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 claims 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 2
- 239000003960 organic solvent Substances 0.000 claims 2
- 238000007151 ring opening polymerisation reaction Methods 0.000 claims 2
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 claims 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 1
- 108010000817 Leuprolide Proteins 0.000 claims 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical group CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical class [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 claims 1
- 239000012867 bioactive agent Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 claims 1
- 230000007062 hydrolysis Effects 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 claims 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 claims 1
- 229960004338 leuprorelin Drugs 0.000 claims 1
- 229940113115 polyethylene glycol 200 Drugs 0.000 claims 1
- 229940068886 polyethylene glycol 300 Drugs 0.000 claims 1
- 230000001376 precipitating effect Effects 0.000 claims 1
- 229960003604 testosterone Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
- C08G63/06—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from hydroxycarboxylic acids
- C08G63/08—Lactones or lactides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/88—Post-polymerisation treatment
- C08G63/90—Purification; Drying
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Polymers & Plastics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pregnancy & Childbirth (AREA)
Claims (15)
1. Biokompatibilan, biorazgradiv, nehidrolizirani PLG kopolimerni materijal sa smanjenim efektom naglog oslobađanja za formulaciju sa kontroliranim oslobađanjem koji ima prosječnu molekularnu masu od oko 10 kilodaltona do oko 50 kilodaltona i indeks polidisperznosti od oko 1.4-2.0 i od kojeg uklonjena kopolimerna frakcija naznačena prosječnom molekularnom masom od oko 4 kDa do oko 10 kDa i indeksom polidisperznosti od oko 1.4 do 2.5 je izdvojena, i koji sadrži kopolimerne molekularne lance, pri čemu pretežni dio molekularnih lanaca sadrži pretežno laktat ili laktid ostatke u najmanje jednoj krajnjoj domeni svakog molekularnog lanca i pretežno glikolat ili glikolid ostatke u unutrašnjoj domeni svakog molekularnog lanca.
2. PLG kopolimerni materijal sa smanjenim efektom naglog oslobađanja iz patentnog zahtjeva 1, gdje PLG kopolimerni materijal sa smanjenim efektom naglog oslobađanja je pripremljen, bez koraka hidrolize PLG kopolimernog materijala sa višom molekularnom masom, od početnog PLG kopolimernog materijala otapanjem polaznog PLG kopolimera u otapalu, taloženjem kopolimernog materijala sa smanjenim efektom naglog oslobađanja sa ne-otapalom, i sakupljanjem PLG kopolimernog materijala sa smanjenim efektom naglog oslobađanja.
3. PLG kopolimerni materijal sa smanjenim efektom naglog oslobađanja iz patentnog zahtjeva 1 ili 2, gdje PLG kopolimerni materijal sa smanjenim efektom naglog oslobađanja ima prosječnu molekularnu masu od oko 15 kDa do oko 50 kDa, i indeks polidisperznosti od oko 1.4-1.8.
4. PLG kopolimerni materijal sa smanjenim efektom naglog oslobađanja iz patentnog zahtjeva 1, gdje sadržaj nereagiranog laktida i glikolida je manji od oko 1.0 masenih % i 0.1 masenih % redom.
5. PLG kopolimerni materijal sa smanjenim efektom naglog oslobađanja iz patentnog zahtjeva 1, gdje uklonjena kopolimerna frakcija je oko 2% do oko 20% po masi od zbira masa uklonjene kopolimerne frakcije i PLG kopolimernog materijala sa smanjenim efektom naglog oslobađanja.
6. PLG kopolimerni materijal sa smanjenim efektom naglog oslobađanja iz patentnog zahtjeva 1, gdje uklonjena kopolimerna frakcija je oko 3% do oko 15% po masi od zbira masa uklonjene kopolimerne frakcije i PLG kopolimernog materijala sa smanjenim efektom naglog oslobađanja.
7. PLG kopolimerni materijal sa smanjenim efektom naglog oslobađanja iz patentnog zahtjeva 1, gdje uklonjena frakcija kopolimera je oko 5% do oko 10% po masi od zbira masa uklonjene kopolimerne frakcije i PLG kopolimernog materijala sa smanjenim efektom naglog oslobađanja.
8. PLG kopolimerni materijal sa smanjenim efektom naglog oslobađanja iz patentnog zahtjeva 1, gdje je početni PLG kopolimerni materijal pripremljen pomoću reakcije polimerizacije laktida i glikolida otvaranjem prstena.
9. PLG kopolimerni materijal sa smanjenim efektom naglog oslobađanja iz patentnog zahtjeva 8, gdje je reakcija polimerizacije laktida i glikolida otvaranjem prstena katalizirana pomoću soli kositra.
10. PLG kopolimerni materijal sa smanjenim efektom naglog oslobađanja iz patentnog zahtjeva 2, gdje otapalo i ne-otapalo se mogu miješati.
11. PLG kopolimerni materijal sa smanjenim efektom naglog oslobađanja iz patentnog zahtjeva 10, gdje je otapalo diklorometan ili kloroform i ne-otapalo je metanol ili etanol.
12. Formulacija sa kontroliranim oslobađanjem koja sadrži protočni sistem za isporuku koji sadrži PLG kopolimerni materijal sa smanjenim efektom naglog oslobađanja iz bilo kojeg od patentnih zahtjeva 1 do 11, organski otapalo, i leuprolid kao bioaktivni agens.
13. Formulacija sa kontroliranim oslobađanjem iz patentnog zahtjeva 12, gdje je organsko otapalo N-metilpirolidon, N,N-dimetilformamid, N,N-dimetilacetamid, dimetilsulfoksid, polietilen glikol 200, polietilen glikol 300, ili metoksipolietilen glikol 350.
14. Formulacija sa kontroliranim oslobađanjem iz patentnog zahtjeva 12 ili patentnog zahtjeva 13 za primjenu u suzbijanju biosinteze testosterona kod muškaraca.
15. Formulacija sa kontroliranim oslobađanjem iz patentnog zahtjeva 12 ili patentnog zahtjeva 13 za primjenu u liječenju raka prostate.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90143507P | 2007-02-15 | 2007-02-15 | |
| EP15185218.3A EP3202814B1 (en) | 2007-02-15 | 2008-02-13 | Low burst poly-(lactide/glycolide) and methods to produce polymers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20192055T1 true HRP20192055T1 (hr) | 2020-02-21 |
Family
ID=39504385
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231117TT HRP20231117T3 (hr) | 2007-02-15 | 2008-02-13 | Poli-(laktid-ko-glikolid) sa smanjenim efektom naglog oslobađanja |
| HRP20150997TT HRP20150997T1 (hr) | 2007-02-15 | 2015-09-21 | Poli-(laktid/glikolid) sa smanjenim efektom naglog oslobađanja i postupci proizvodnje polimera |
| HRP20192055TT HRP20192055T1 (hr) | 2007-02-15 | 2019-11-14 | Poli-(laktid/glikolid) sa smanjenim efektom naglog oslobađanja i metode za proizvodnju polimera |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231117TT HRP20231117T3 (hr) | 2007-02-15 | 2008-02-13 | Poli-(laktid-ko-glikolid) sa smanjenim efektom naglog oslobađanja |
| HRP20150997TT HRP20150997T1 (hr) | 2007-02-15 | 2015-09-21 | Poli-(laktid/glikolid) sa smanjenim efektom naglog oslobađanja i postupci proizvodnje polimera |
Country Status (16)
| Country | Link |
|---|---|
| US (7) | US9187593B2 (hr) |
| EP (3) | EP3660073B1 (hr) |
| JP (3) | JP5342459B2 (hr) |
| CA (1) | CA2678350C (hr) |
| CY (2) | CY1116785T1 (hr) |
| DK (3) | DK3202814T3 (hr) |
| ES (3) | ES2755374T3 (hr) |
| FI (1) | FI3660073T3 (hr) |
| HK (1) | HK1138303A1 (hr) |
| HR (3) | HRP20231117T3 (hr) |
| HU (3) | HUE063170T2 (hr) |
| LT (2) | LT3202814T (hr) |
| PL (3) | PL2115029T3 (hr) |
| PT (3) | PT3660073T (hr) |
| SI (3) | SI3202814T1 (hr) |
| WO (1) | WO2008100532A1 (hr) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8313763B2 (en) * | 2004-10-04 | 2012-11-20 | Tolmar Therapeutics, Inc. | Sustained delivery formulations of rapamycin compounds |
| US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
| US20070196416A1 (en) | 2006-01-18 | 2007-08-23 | Quest Pharmaceutical Services | Pharmaceutical compositions with enhanced stability |
| SI3202814T1 (sl) | 2007-02-15 | 2019-12-31 | Tolmar Therapeutics, Inc. | Poli-(laktid/glikolid) z nizkim razpokom in postopki za proizvodnjo polimerov |
| MX354603B (es) | 2007-05-25 | 2018-03-13 | Indivior Uk Ltd | Formulaciones de transferencia sostenida de compuestos de risperidona. |
| WO2009148580A2 (en) * | 2008-06-03 | 2009-12-10 | Qlt Usa, Inc. | Controlled release copolymer formulation with improved release kinetics |
| US10335366B2 (en) | 2010-05-31 | 2019-07-02 | Laboratorios Farmacéuticos Rovi, S.A. | Risperidone or paliperidone implant formulation |
| US10285936B2 (en) | 2010-05-31 | 2019-05-14 | Laboratorios Farmacéuticos Rovi, S.A. | Injectable composition with aromatase inhibitor |
| US10350159B2 (en) | 2010-05-31 | 2019-07-16 | Laboratories Farmacéuticos Rovi, S.A. | Paliperidone implant formulation |
| US10463607B2 (en) | 2010-05-31 | 2019-11-05 | Laboratorios Farmaceutics Rofi S.A. | Antipsychotic Injectable Depot Composition |
| PL2394663T3 (pl) | 2010-05-31 | 2022-02-21 | Laboratorios Farmaceuticos Rovi, S.A. | Kompozycje do wstrzykiwania implantów biodegradowalnych in-situ |
| ES2589106T3 (es) | 2010-05-31 | 2016-11-10 | Laboratorios Farmaceuticos Rovi, S.A. | Composición inyectable antipsicótica de liberación controlada |
| US10881605B2 (en) | 2010-05-31 | 2021-01-05 | Laboratorios Farmaceuticos Rovi, S.A. | Methods for the preparation of injectable depot compositions |
| GB2481018B (en) | 2010-06-08 | 2015-03-18 | Rb Pharmaceuticals Ltd | Injectable flowable composition comprising buprenorphine |
| US9272044B2 (en) | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
| GB2513060B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
| CN103421172B (zh) * | 2012-05-23 | 2016-01-20 | 上海现代药物制剂工程研究中心有限公司 | 一种生物可降解聚酯的纯化工艺 |
| CA2903769A1 (en) | 2013-03-11 | 2014-10-09 | Durect Corporation | Injectable controlled release composition comprising high viscosity liquid carrier |
| US20140308352A1 (en) | 2013-03-11 | 2014-10-16 | Zogenix Inc. | Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material |
| WO2014168134A1 (ja) | 2013-04-11 | 2014-10-16 | 三井化学株式会社 | 乳酸―グリコール酸共重合体の製造法またはその塩の製造法 |
| US20160296627A1 (en) * | 2013-12-06 | 2016-10-13 | Envisia Therapeutics Inc. | Intracameral implant for treatment of an ocular condition |
| GB201404139D0 (en) | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
| US20160106804A1 (en) * | 2014-10-15 | 2016-04-21 | Yuhua Li | Pharmaceutical composition with improved stability |
| US11000520B2 (en) | 2014-11-07 | 2021-05-11 | Indivior Uk Limited | Buprenorphine dosing regimens |
| US11458041B2 (en) | 2015-10-08 | 2022-10-04 | Ocular Therapeutix, Inc. | Punctal plug and bioadhesives |
| US10646484B2 (en) | 2017-06-16 | 2020-05-12 | Indivior Uk Limited | Methods to treat opioid use disorder |
| CN112545995B (zh) * | 2018-05-16 | 2024-02-23 | 珠海市丽珠微球科技有限公司 | 一种阿立哌唑缓释微球及其制备方法 |
| ES2952213T3 (es) | 2020-02-06 | 2023-10-30 | Ocular Therapeutix Inc | Composiciones y métodos para tratar enfermedades oculares |
| EP4221684A1 (en) | 2020-09-30 | 2023-08-09 | Tolmar International Limited | Biodegradable polymer delivery system for extended delivery of testosterone |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2551756B2 (ja) * | 1985-05-07 | 1996-11-06 | 武田薬品工業株式会社 | ポリオキシカルボン酸エステルおよびその製造法 |
| DE3641692A1 (de) | 1986-12-06 | 1988-06-09 | Boehringer Ingelheim Kg | Katalysatorfreie resorbierbare homopolymere und copolymere |
| DE3708916A1 (de) | 1987-03-19 | 1988-09-29 | Boehringer Ingelheim Kg | Verfahren zur reinigung resorbierbarer polyester |
| US5702716A (en) | 1988-10-03 | 1997-12-30 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
| US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
| US5324519A (en) | 1989-07-24 | 1994-06-28 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
| US5487897A (en) | 1989-07-24 | 1996-01-30 | Atrix Laboratories, Inc. | Biodegradable implant precursor |
| ATE168391T1 (de) | 1990-04-13 | 1998-08-15 | Takeda Chemical Industries Ltd | Biologisch abbaubare hochmolekulare polymere, ihre herstellung und ihre verwendung |
| USRE37950E1 (en) | 1990-04-24 | 2002-12-31 | Atrix Laboratories | Biogradable in-situ forming implants and methods of producing the same |
| US6353030B1 (en) * | 1990-08-01 | 2002-03-05 | Novartis Ag | Relating to organic compounds |
| AU2605592A (en) | 1991-10-15 | 1993-04-22 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
| EP0560014A1 (en) | 1992-03-12 | 1993-09-15 | Atrix Laboratories, Inc. | Biodegradable film dressing and method for its formation |
| US5681873A (en) | 1993-10-14 | 1997-10-28 | Atrix Laboratories, Inc. | Biodegradable polymeric composition |
| DE69524398T2 (de) | 1994-04-08 | 2002-07-18 | Atrix Lab Inc | Flüssige mittel zur wirkstoffabgabe |
| AU5004196A (en) | 1995-03-10 | 1996-10-02 | Boehringer Mannheim Gmbh | Polypeptide-containing pharmaceutical forms of administration in the form of microparticles and method for the preparation thereof |
| US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| JP4317599B2 (ja) | 1996-06-26 | 2009-08-19 | 武田薬品工業株式会社 | 徐放性製剤 |
| IL135415A0 (en) | 1997-10-03 | 2001-05-20 | Macromed Inc | Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties |
| US6261583B1 (en) | 1998-07-28 | 2001-07-17 | Atrix Laboratories, Inc. | Moldable solid delivery system |
| US6565874B1 (en) | 1998-10-28 | 2003-05-20 | Atrix Laboratories | Polymeric delivery formulations of leuprolide with improved efficacy |
| US6143314A (en) | 1998-10-28 | 2000-11-07 | Atrix Laboratories, Inc. | Controlled release liquid delivery compositions with low initial drug burst |
| US6355657B1 (en) | 1998-12-30 | 2002-03-12 | Atrix Laboratories, Inc. | System for percutaneous delivery of opioid analgesics |
| US6461631B1 (en) | 1999-11-16 | 2002-10-08 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
| DE60118575T3 (de) | 2000-08-07 | 2011-05-19 | Takeda Pharmaceutical Co. Ltd. | Milchsäurepolymer und verfahren zu dessen herstellung |
| TWI225416B (en) | 2001-06-29 | 2004-12-21 | Takeda Chemical Industries Ltd | Sustained-release composition and process for producing the same |
| JP5188670B2 (ja) | 2001-06-29 | 2013-04-24 | 武田薬品工業株式会社 | 徐放性組成物およびその製造法 |
| US20060034889A1 (en) * | 2004-08-16 | 2006-02-16 | Macromed, Inc. | Biodegradable diblock copolymers having reverse thermal gelation properties and methods of use thereof |
| BRPI0516308A2 (pt) * | 2004-10-04 | 2010-06-15 | Qlt Usa Inc | composição fluida, métodos de tratamento de uma doença ou disfunção, métodos de liberação local ou sistêmica de um agente biológico, implantes, método de formação de um implante, kit de agente biológico e usos de uma composição fluida |
| CA2586846C (en) * | 2004-11-10 | 2013-12-31 | Qlt Usa Inc. | A stabilized polymeric delivery system |
| EP2079767B1 (en) * | 2006-10-11 | 2014-08-27 | Tolmar Therapeutics, Inc. | Preparation of biodegradable polyesters with low-burst properties by supercritical fluid extraction |
| SI3202814T1 (sl) | 2007-02-15 | 2019-12-31 | Tolmar Therapeutics, Inc. | Poli-(laktid/glikolid) z nizkim razpokom in postopki za proizvodnjo polimerov |
-
2008
- 2008-02-13 SI SI200832098T patent/SI3202814T1/sl unknown
- 2008-02-13 LT LT15185218T patent/LT3202814T/lt unknown
- 2008-02-13 HR HRP20231117TT patent/HRP20231117T3/hr unknown
- 2008-02-13 DK DK15185218T patent/DK3202814T3/da active
- 2008-02-13 HU HUE19203071A patent/HUE063170T2/hu unknown
- 2008-02-13 HU HUE08725511A patent/HUE025842T2/en unknown
- 2008-02-13 SI SI200832213T patent/SI3660073T1/sl unknown
- 2008-02-13 PT PT192030716T patent/PT3660073T/pt unknown
- 2008-02-13 US US12/527,377 patent/US9187593B2/en not_active Expired - Fee Related
- 2008-02-13 WO PCT/US2008/001887 patent/WO2008100532A1/en active Application Filing
- 2008-02-13 EP EP19203071.6A patent/EP3660073B1/en active Active
- 2008-02-13 HU HUE15185218A patent/HUE047775T2/hu unknown
- 2008-02-13 DK DK19203071.6T patent/DK3660073T3/da active
- 2008-02-13 PT PT87255113T patent/PT2115029E/pt unknown
- 2008-02-13 EP EP08725511.3A patent/EP2115029B1/en active Active
- 2008-02-13 CA CA2678350A patent/CA2678350C/en not_active Expired - Fee Related
- 2008-02-13 EP EP15185218.3A patent/EP3202814B1/en active Active
- 2008-02-13 ES ES15185218T patent/ES2755374T3/es active Active
- 2008-02-13 DK DK08725511.3T patent/DK2115029T3/en active
- 2008-02-13 ES ES08725511.3T patent/ES2550014T3/es active Active
- 2008-02-13 PL PL08725511T patent/PL2115029T3/pl unknown
- 2008-02-13 ES ES19203071T patent/ES2956244T3/es active Active
- 2008-02-13 FI FIEP19203071.6T patent/FI3660073T3/fi active
- 2008-02-13 SI SI200831512T patent/SI2115029T1/sl unknown
- 2008-02-13 PL PL15185218T patent/PL3202814T3/pl unknown
- 2008-02-13 PL PL19203071.6T patent/PL3660073T3/pl unknown
- 2008-02-13 PT PT151852183T patent/PT3202814T/pt unknown
- 2008-02-13 JP JP2009550095A patent/JP5342459B2/ja active Active
- 2008-02-13 LT LTEP19203071.6T patent/LT3660073T/lt unknown
-
2010
- 2010-05-10 HK HK10104526.3A patent/HK1138303A1/xx unknown
-
2013
- 2013-08-09 JP JP2013166807A patent/JP5848290B2/ja active Active
-
2015
- 2015-04-10 JP JP2015080726A patent/JP6195587B2/ja active Active
- 2015-09-21 HR HRP20150997TT patent/HRP20150997T1/hr unknown
- 2015-10-08 CY CY20151100906T patent/CY1116785T1/el unknown
- 2015-10-27 US US14/924,243 patent/US9561282B2/en active Active
-
2016
- 2016-12-19 US US15/384,117 patent/US9655970B2/en active Active
-
2017
- 2017-04-18 US US15/490,615 patent/US9974824B2/en active Active
-
2018
- 2018-04-10 US US15/950,024 patent/US10206970B2/en active Active
-
2019
- 2019-01-08 US US16/242,316 patent/US11147880B2/en active Active
- 2019-11-14 HR HRP20192055TT patent/HRP20192055T1/hr unknown
- 2019-11-18 CY CY20191101209T patent/CY1122304T1/el unknown
-
2021
- 2021-09-16 US US17/477,361 patent/US11717572B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20192055T1 (hr) | Poli-(laktid/glikolid) sa smanjenim efektom naglog oslobađanja i metode za proizvodnju polimera | |
| WO2012054923A3 (en) | Therapeutic nanoparticles with high molecular weight copolymers | |
| WO2010091187A3 (en) | Polymeric nanoparticles with enhanced drug-loading and methods of use thereof | |
| GB201105455D0 (en) | Blends of a polylactic acid and a water soluble polymer | |
| WO2011112482A3 (en) | Polymeric drug delivery conjugates and methods of making and using thereof | |
| CN103055354B (zh) | 一种生物可降解的医用手术防粘连膜及其制备方法 | |
| CN103159956B (zh) | 一种芳香族-脂肪族可降解接枝聚合物 | |
| WO2008036274A3 (en) | Low voc coating compositions comprising low molecular weight cellulose mixed esters and low molecular weight hydroxyl-containing polymers | |
| WO2012103208A3 (en) | Compositions of glycidyl methacrylate copolymer suitable as chain extender for poly(lactic acid) | |
| WO2011053958A3 (en) | Toughened poly(trimethylene terephthalate) compositions and molded articles therefrom | |
| DE602005019546D1 (de) | Verzweigte Polymere, ein makromonomer, Verfahren zu deren Herstellungen und deren Verwendungen | |
| Akopova et al. | Solid state synthesis and modification of chitosan | |
| WO2003078517A3 (en) | Compositions based on expandable vinylaromatic polymers with an improved expandability | |
| Khamsarn et al. | PLA with high elongation induced by multi-branched poly (ethylene imine)(mPEI) containing poly (l-lactic acid)(PLLA) terminals | |
| RU2012111986A (ru) | Полимеры, способные к восстановлению и обратимому термическому гелеобразованию | |
| WO2009119258A1 (ja) | 生体吸収性材料およびそれを用いた生体内留置物 | |
| CN101016372A (zh) | 一种聚乳酸与氨基聚糖接枝共聚材料的制备方法 | |
| Joung et al. | 6-arm PLLA-PEG block copolymers for micelle formation and controlled drug release | |
| Fu et al. | Synthesis of clickable amphiphilic polysaccharides as nanoscopic assemblies | |
| Liu et al. | Synthesis, characterization and structural analysis of polylactide grafted onto water-soluble hydroxypropyl chitin as backbone. | |
| CN104356368A (zh) | 一种聚酯嵌段共聚物 | |
| CN105622950A (zh) | 一种聚乙烯醇-聚三亚甲基碳酸酯-聚乳酸乙醇酸双接枝共聚物的制备方法 | |
| Phuong et al. | Modification of the mechanical behavior in the glass transition region of poly (lactic acid)(PLA) through catalyzed reactive extrusion with poly (carbonate)(PC) | |
| 李悦生 | Synthesis and characterization of hyperbranched poly (ester-amide) s based on gallic acid and DL-2-aminobutyric acid | |
| Czelusniak et al. | Synthesis of biodegradable copolymers |